The global biosimilar monoclonal antibody market is expected to grow at a CAGR of 12.2% during the forecast period, from 2021 to 2030. The growth of this market is driven by factors such as increasing prevalence of chronic and autoimmune diseases, rising demand for cost-effective treatments, and growing number of biopharmaceutical companies entering the market.
The global biosimilar monoclonal antibody market is segmented on the basis of type into synthetic chemicals and biopharmaceuticals. The synthetic chemicals segment accounted for a share of over 50% in 2018 owing to its low cost and easy availability. However, it is expected that the biopharmaceuticals segment will grow at a higher rate during the forecast period owing to its high efficacy rates in comparison with synthetic chemicals.
Oncology accounted for over 40% share in 2018 owing to its high incidence rates globally as well as increasing demand for cancer treatments across various geographies. Chronic & autoimmune diseases are also expected to witness significant growth during the forecast period due to their rising prevalence rates globally coupled with increased awareness about their treatment options among patients suffering from these conditions.
- Increasing awareness about the benefits of biosimilars over their branded counterparts is also expected to drive growth in this market during the forecast period.
- In addition, increasing government support for healthcare expenditure and rising disposable income are also expected to fuel growth in this market.
- Furthermore, technological advancements in biotechnology are anticipated to provide an impetus for growth in this market 5.However, stringent regulatory requirements pertaining to safety and efficacy may pose challenges for manufacturers.
Industry Growth Insights published a new data on “Biosimilar Monoclonal Antibody Market”. The research report is titled “Biosimilar Monoclonal Antibody Market research by Types (Synthetic Chemicals, Biopharmaceuticals, Others), By Applications (Chronic & Autoimmune Diseases, Oncology, Others), By Players/Companies Biocon, Accord Healthcare, AET Biotech, Amgen, Celltrion, Reddy's Laboratories, Hospira, 3SBio, Allergan, Alvartis”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Biosimilar Monoclonal Antibody Market Research Report
By Type
Synthetic Chemicals, Biopharmaceuticals, Others
By Application
Chronic & Autoimmune Diseases, Oncology, Others
By Companies
Biocon, Accord Healthcare, AET Biotech, Amgen, Celltrion, Reddy's Laboratories, Hospira, 3SBio, Allergan, Alvartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Biosimilar Monoclonal Antibody Market Report Segments:
The global Biosimilar Monoclonal Antibody market is segmented on the basis of:
Types
Synthetic Chemicals, Biopharmaceuticals, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic & Autoimmune Diseases, Oncology, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biocon
- Accord Healthcare
- AET Biotech
- Amgen
- Celltrion
- Reddy's Laboratories
- Hospira
- 3SBio
- Allergan
- Alvartis
Highlights of The Biosimilar Monoclonal Antibody Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Synthetic Chemicals
- Biopharmaceuticals
- Others
- By Application:
- Chronic & Autoimmune Diseases
- Oncology
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Biosimilar Monoclonal Antibody Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A biosimilar monoclonal antibody is a type of biologic drug that is similar to an existing medication but has been modified so that it does not produce the same side effects in humans.
Some of the major companies in the biosimilar monoclonal antibody market are Biocon, Accord Healthcare, AET Biotech, Amgen, Celltrion, Reddy's Laboratories, Hospira, 3SBio, Allergan, Alvartis.
The biosimilar monoclonal antibody market is expected to grow at a compound annual growth rate of 12.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Biosimilar Monoclonal Antibody Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Biosimilar Monoclonal Antibody Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Biosimilar Monoclonal Antibody Market - Supply Chain
4.5. Global Biosimilar Monoclonal Antibody Market Forecast
4.5.1. Biosimilar Monoclonal Antibody Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Biosimilar Monoclonal Antibody Market Size (000 Units) and Y-o-Y Growth
4.5.3. Biosimilar Monoclonal Antibody Market Absolute $ Opportunity
5. Global Biosimilar Monoclonal Antibody Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Type
5.3.1. Synthetic Chemicals
5.3.2. Biopharmaceuticals
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Biosimilar Monoclonal Antibody Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Application
6.3.1. Chronic & Autoimmune Diseases
6.3.2. Oncology
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Biosimilar Monoclonal Antibody Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Biosimilar Monoclonal Antibody Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Biosimilar Monoclonal Antibody Demand Share Forecast, 2019-2029
9. North America Biosimilar Monoclonal Antibody Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Application
9.4.1. Chronic & Autoimmune Diseases
9.4.2. Oncology
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Type
9.7.1. Synthetic Chemicals
9.7.2. Biopharmaceuticals
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Biosimilar Monoclonal Antibody Demand Share Forecast, 2019-2029
10. Latin America Biosimilar Monoclonal Antibody Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Application
10.4.1. Chronic & Autoimmune Diseases
10.4.2. Oncology
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Type
10.7.1. Synthetic Chemicals
10.7.2. Biopharmaceuticals
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Biosimilar Monoclonal Antibody Demand Share Forecast, 2019-2029
11. Europe Biosimilar Monoclonal Antibody Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Application
11.4.1. Chronic & Autoimmune Diseases
11.4.2. Oncology
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Type
11.7.1. Synthetic Chemicals
11.7.2. Biopharmaceuticals
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Biosimilar Monoclonal Antibody Demand Share, 2019-2029
12. Asia Pacific Biosimilar Monoclonal Antibody Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Application
12.4.1. Chronic & Autoimmune Diseases
12.4.2. Oncology
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Type
12.7.1. Synthetic Chemicals
12.7.2. Biopharmaceuticals
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Biosimilar Monoclonal Antibody Demand Share, 2019-2029
13. Middle East & Africa Biosimilar Monoclonal Antibody Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Application
13.4.1. Chronic & Autoimmune Diseases
13.4.2. Oncology
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Biosimilar Monoclonal Antibody Market Size and Volume Forecast by Type
13.7.1. Synthetic Chemicals
13.7.2. Biopharmaceuticals
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Biosimilar Monoclonal Antibody Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Biosimilar Monoclonal Antibody Market: Market Share Analysis
14.2. Biosimilar Monoclonal Antibody Distributors and Customers
14.3. Biosimilar Monoclonal Antibody Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Biocon
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Accord Healthcare
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AET Biotech
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Amgen
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Celltrion
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Reddy's Laboratories
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hospira
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. 3SBio
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Allergan
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Alvartis
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
